18264-Biliary Cancer-NA-1519

Biliary Cancer

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Address

1105 Central Expressway, Suite 320
Allen, TX 75013
P: (469) 467-4392

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.